Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT
LECANKITUG INJECTION INCLUDED IN THE PRIORITY REVIEW AND APPROVAL PROCESS

Lecankitug Injection (莱康奇塔單抗注射液) (the "**Drug**"), jointly developed by Livzon MABPharm Inc.* (珠海市麗珠單抗生物技術有限公司) ("**Livzon MAB**"), a controlling subsidiary of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "**Company**"), and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd.* (北京鑫康合生物醫藥科技有限公司), was included in the Public List of Drugs Proposed for Priority Review (擬優先審評品種公示名單) by the Center for Drug Evaluation of the National Medical Products Administration ("**NMPA**") On 26 December 2025. Upon expiration of the public notice period, and as disclosed on the website of Center for Drug Evaluation of NMPA, the Drug has been included in the Public List of Drugs for Priority Review (優先審評品種公示名單), and has officially entered the priority review and approval process for marketing authorisation. Relevant details are announced as follows:

BASIC INFORMATION OF THE DRUG

Drug Name: 莱康奇塔單抗注射液
English/Latin name: Lecankitug Injection
Applicant for Market Launch: Livzon MABPharm Inc.* (珠海市麗珠單抗生物技術有限公司)
Application Date: 18 December 2025
Public Notice Date: 26 December 2025
Acceptance Number: CXSS2500144
Proposed Indication (or main treatments): The Drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Reason for Inclusion in Priority Review: Upon review, this application has been deemed compliant with the relevant requirements of the Drug Registration Administration Measures and the Announcement of the National Medical Products Administration on Issuing Three Documents Including the "Review Working Procedures for Breakthrough Therapy Drugs (Trial)" (No.82, 2020). It is approved for inclusion in the priority review and approval process under the category of priority review: (6) Other circumstances specified by the National Medical Products Administration that qualify for priority review and approval.

OTHER RELEVANT INFORMATION

Psoriasis is a chronic inflammatory skin disease induced by a combination of genetic, immune, and environmental factors, affecting approximately 100 million patients globally. Lecankitug Injection, as the first domestically developed and the second globally developed innovative dual IL-17A/F inhibitor, exerts its effect by simultaneously blocking the pro-inflammatory factors IL-17A and IL-17F. In July 2025, the multicentre, randomized, double-blind, active-controlled (vs. secukinumab) clinical trial of the Drug in patients with moderate-to-severe plaque psoriasis met both the primary and secondary efficacy endpoints. Study results showed that compared to the control group (secukinumab), the Drug demonstrated superior PASI 100 response rate at week 12, PASI 75 response rate at week 4, and PASI 100 response rate at week 52, reflecting its characteristics of rapid onset, excellent short-term efficacy, long-lasting durability, and lower dosing frequency. The Drug demonstrated a favorable safety profile, with the incidence of common adverse events comparable to that of various adverse events in the control group. For specific details regarding the clinical trial of the Drug, please refer to the Company's Voluntary Announcement on Achievement of The Primary Endpoint in Phase III Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection disclosed on 21 July 2025.

The Drug is jointly developed by Livzon MAB and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd.* (北京鑫康合生物醫藥科技有限公司).

RISK WARNING

In accordance with the relevant laws and regulations governing drug registration, the new drug marketing authorization application shall undergo procedures including review, on-site inspection of clinical trials, and approval. There is uncertainty as to whether the Product will ultimately obtain marketing approval or its expected timeline for launch. Furthermore, the competitive landscape for the product may change with market conditions. The Company will closely monitor the subsequent progress of the registration application and timely fulfill its information disclosure obligations. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
7 January 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director of the Company is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

* *For identification purpose only*